Q-omics provides the consensus-scored MUC12 profile across patient tissues and cancer cell-line models. MUC12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MUC12 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MUC12 RNA expression shows 16,163 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where MUC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC12 survival associations across molecular data types. MUC12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC12 RNA expression–survival associations across cancer types. High MUC12 expression shows unfavorable associations in KIRC, MESO, UVM, UCS, ACC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MUC12 RNA expression.
This table summarizes MUC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MUC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC12 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and STAD. The KIRC box plot shows higher MUC12 RNA expression in tumor versus normal tissue (log2 FC = +0.482, t-test p < 0.001).
This table shows molecular features associated with MUC12 in patient tissues and cancer cell lines. In patient samples, MUC12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
